Diagnosis and treatment of patients with NSCLC EGFR Mut+

Abstract

Using tyrosine kinase inhibitors in the second line of treatment in patients with adenocarcinoma and EGFR activated mutation may slightly prolong the survival time. In patients with adenocarcinoma, with a positive mutation in the EGFR gene and progression after treatment of chemioterapy platinum-based — the drug of choice is erlotinib at a daily dose 150 mg. The case study present a few months survival without progression patient with diagnosis NSCLC EGFR Mut+ treated with erlotinib in the second line.